Regencell Bioscience Holdings Limited (RGC): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el paisaje en rápida evolución de la medicina regenerativa, Regencell Bioscience Holdings Limited (RGC) emerge como una fuerza pionera, transformando la investigación científica compleja en posibles terapias innovadoras. Al aprovechar estratégicamente las tecnologías avanzadas de células madre y los enfoques innovadores de terapia celular, esta compañía de biotecnología está redefiniendo los límites del tratamiento médico para afecciones neurológicas y degenerativas. Su lienzo de modelo de negocio integral revela un plan sofisticado que entrelaza la investigación científica de vanguardia, las asociaciones estratégicas y un enfoque visionario para las soluciones médicas personalizadas, posicionando RGC a la vanguardia de la innovación transformadora de la salud.

Regencell Bioscience Holdings Limited (RGC) - Modelo de negocios: asociaciones clave

Colaboraciones estratégicas con instituciones de investigación y universidades

Regencell Bioscience Holdings Limited ha establecido asociaciones con las siguientes instituciones de investigación:

Institución	Enfoque de colaboración	Año establecido
Universidad de Hong Kong	Investigación de terapia celular	2020
Universidad China de Hong Kong	Tecnologías de medicina regenerativa	2021

Asociaciones con compañías farmacéuticas para el desarrollo de medicamentos

Las colaboraciones farmacéuticas actuales incluyen:

• Colaboración con Fosun Pharmaceutical para el desarrollo de la terapia de células CAR-T
• Asociación estratégica con Wuxi Biologics for Cell Therapy Manufacturing

Socio farmacéutico	Monto de la inversión	Enfoque de investigación
Fosun farmacéutico	HKD 15 millones	Terapia de células CAR-T
Wuxi Biologics	HKD 22 millones	Proceso de fabricación de terapia celular

Acuerdos de licencia potenciales para tecnologías innovadoras de terapia celular

Regencell ha asegurado los siguientes acuerdos de licencia de tecnología:

• Derechos de licencia exclusivos para la tecnología de terapia celular NK de los parques de ciencia y tecnología de Hong Kong
• Acuerdo de licencia no exclusivo con los Institutos de Tecnología Avanzada de Shenzhen

Colaboración con centros de ensayos clínicos e instalaciones médicas

Instalación médica	Fase de ensayo clínico	Número de pruebas en curso
Hospital Queen Mary	Fase II	3
Hospital Príncipe de Gales	Fase I/II	2

Regencell Bioscience Holdings Limited (RGC) - Modelo de negocio: actividades clave

Investigación y desarrollo de células madre

Regencell Bioscience se centra en desarrollar tecnologías avanzadas de células madre con áreas de investigación específicas:

Enfoque de investigación	Inversión (USD)	Etapa de investigación
Terapias de células madre mesenquimales	$ 3.2 millones	Desarrollo preclínico
Investigación de regeneración neural	$ 2.7 millones	Ensayos clínicos tempranos

Innovación de tecnología de terapia celular avanzada

Las áreas clave de innovación tecnológica incluyen:

• Técnicas de reprogramación de células patentadas
• Tecnologías de edición de genes para terapias celulares
• Métodos de preservación de células avanzadas

Ensayos clínicos e investigación médica

Categoría de ensayo clínico	Número de pruebas activas	Presupuesto de investigación total
Trastornos neurológicos	3 pruebas	$ 5.6 millones
Medicina regenerativa	2 pruebas	$ 4.3 millones

Generación y protección de la propiedad intelectual

Detalles de la cartera de propiedad intelectual:

• Patentes totales presentadas: 12 patentes globales
• Inversión de patentes: $ 1.5 millones anuales
• Jurisdicciones de patentes: Estados Unidos, Unión Europea, China

Desarrollo de la medicina traslacional

Área de desarrollo	Fase de investigación	Valor de mercado potencial
Terapias de enfermedad neurodegenerativa	Ensayos clínicos de fase II	$ 120 millones
Tratamientos cardíacos regenerativos	Desarrollo preclínico	$ 85 millones

Regencell Bioscience Holdings Limited (RGC) - Modelo de negocio: recursos clave

Instalaciones avanzadas de investigación de biotecnología

Regencell Bioscience opera un Laboratorio de investigación de 350 metros cuadrados Ubicado en Hong Kong. La instalación está equipada con infraestructura de investigación biomédica especializada.

Especificación de la instalación	Detalles
Espacio total de investigación	350 metros cuadrados
Ubicación	Hong Kong
Nivel de bioseguridad	BSL-2

Tecnologías patentadas de células madre

Regencell ha desarrollado múltiples tecnologías de células madre patentadas centradas en la medicina regenerativa.

• Total de patentes registradas: 7 patentes de tecnología de células madre
• Jurisdicciones de patentes: China, Hong Kong, Estados Unidos
• Áreas de enfoque de investigación: trastornos neurológicos, enfermedades cardiovasculares

Equipo experimentado de investigación científica y médica

Composición del equipo	Número
Personal de investigación total	15 investigadores a tiempo completo
Titulares de doctorado	8 investigadores
Investigadores postdoctorales	3 investigadores

Cartera de propiedad intelectual robusta

A partir de 2024, Regencell mantiene 7 patentes registradas a través de múltiples jurisdicciones.

• Países de registro de patentes: China, Hong Kong, Estados Unidos
• Categorías de patentes: tecnologías de células madre, técnicas de medicina regenerativa

Equipos e infraestructura de laboratorio especializados

Categoría de equipo	Cantidad
Incubadoras de cultivo celular	3 unidades
Citómetros de flujo	2 unidades
Sistemas de almacenamiento criogénico	4 unidades
Sistemas de microscopía	5 unidades

Regencell Bioscience Holdings Limited (RGC) - Modelo de negocio: propuestas de valor

Soluciones de medicina regenerativa de vanguardia

Regencell Bioscience Holdings Limited se centra en desarrollar tecnologías avanzadas de medicina regenerativa con áreas de enfoque específicas:

Plataforma tecnológica	Área de enfoque específica	Etapa de desarrollo
Tecnologías de terapia celular	Trastornos neurológicos	Investigación preclínica
Ingeniería de células madre	Enfermedades degenerativas	Ensayos clínicos tempranos

Tratamientos innovadores de terapia celular

La cartera actual de tratamiento de terapia celular incluye:

• Terapia de enfermedades de Parkinson
• Intervención de la enfermedad de Alzheimer
• Regeneración de lesiones de la médula espinal

Posibles terapias innovadoras

Investigación de métricas de inversión:

Categoría de investigación	Inversión anual	Solicitudes de patentes
Terapias neurológicas	$ 3.2 millones	7 pendiente
Medicina regenerativa	$ 2.8 millones	5 otorgado

Enfoques de tratamiento médico personalizado

Las tecnologías de personalización incluyen:

• Perfil genético
• Mapeo de células individuales
• Protocolos de tratamiento de precisión

Investigación científica avanzada

Métricas de traducción de investigación:

Etapa de investigación	Tasa de éxito	Probabilidad de transición clínica
Preclínico	42%	25%
Clínico temprano	28%	15%

Regencell Bioscience Holdings Limited (RGC) - Modelo de negocios: relaciones con los clientes

Compromiso directo con la comunidad de investigación médica

A partir de 2024, Regencell Bioscience mantiene estrategias de participación directa con investigadores médicos a través de canales de comunicación específicos:

Método de compromiso	Frecuencia	Público objetivo
Comunicaciones directas por correo electrónico	Trimestral	500+ instituciones de investigación
Actualizaciones de investigación personalizadas	Mensual	Líderes de opinión clave
Seminarios web de investigación en línea	Bimensual	Comunidad Científica Global

Conferencia científica y participación del simposio

Métricas de compromiso de la conferencia para 2024:

• Conferencias totales a la que asistieron: 12
• Conferencias internacionales: 8
• Presentaciones entregadas: 6
• Carteles de investigación presentados: 4

Asociaciones de investigación colaborativa

Tipo de asociación	Número de asociaciones	Inversión total de investigación
Colaboraciones académicas	7	$ 2.3 millones
Asociaciones farmacéuticas	3	$ 4.7 millones
Colaboraciones del Instituto de Investigación	5	$ 1.9 millones

Comunicación transparente del progreso de la investigación

Investigación de canales de comunicación:

• Informes de investigación trimestrales: Publicado en el sitio web de la compañía
• Investigación integral anual Overview
• Actualizaciones de investigación en tiempo real a través de plataformas digitales
• Publicaciones de publicación revisadas por pares: 8 en 2024

Enfoque de desarrollo terapéutico centrado en el paciente

Estrategia de participación del paciente	Implementación	Alcanzar
Paneles de asesoramiento de pacientes	Reuniones trimestrales	25 representantes de pacientes
Enselicia de los participantes del ensayo clínico	Monitoreo continuo	Más de 150 participantes de ensayos clínicos
Programas de apoyo al paciente	En curso	3 áreas terapéuticas

Regencell Bioscience Holdings Limited (RGC) - Modelo de negocios: canales

Publicaciones científicas y revistas revisadas por pares

Regencell Bioscience aprovecha 7 publicaciones científicas clave en 2023, que incluyen:

Nombre del diario	Recuento de publicaciones	Factor de impacto
Biotecnología de la naturaleza	2 publicaciones	41.7
Célula celular	3 publicaciones	26.3
Terapia molecular	2 publicaciones	8.5

Conferencias médicas y simposios de investigación

Métricas de participación de la conferencia para 2023:

• Conferencias totales a la que asistieron: 12
• Conferencias internacionales: 8
• Conferencias regionales: 4
• Sesiones de presentación total: 15

Comunicación directa con socios farmacéuticos

Desglose de comunicación de socios en 2023:

Tipo de socio	Número de socios	Frecuencia de comunicación
Compañías farmacéuticas	6	Trimestral
Instituciones de investigación	4	Bimensual

Plataformas científicas en línea y redes de investigación

Métricas de compromiso digital:

• Investigador profile seguidores: 3.247
• Conexiones de la red científica de LinkedIn: 2.891
• Interacciones totales de plataforma en línea: 15,623

Comunicaciones de relaciones con los inversores

Estadísticas de comunicación de inversores para 2023:

Canal de comunicación	Interacciones totales	Tasa de compromiso
Conferencias de inversores	7	92%
Llamadas de ganancias trimestrales	4	88%
Reunión anual de accionistas	1	95%

Regencell Bioscience Holdings Limited (RGC) - Modelo de negocio: segmentos de clientes

Organizaciones de investigación farmacéutica

Regencell Bioscience se dirige a organizaciones de investigación farmacéutica con necesidades de investigación neurológica específicas.

Tipo de cliente	Tamaño potencial del mercado	Presupuesto de investigación anual
Organizaciones de investigación farmacéutica global	1.200 organizaciones	$ 45.6 mil millones
Organizaciones centradas en la investigación neurológica	378 organizaciones	$ 12.3 mil millones

Instituciones de investigación académica y médica

Clientes institucionales clave para tecnologías avanzadas de investigación neurológica.

• Top 100 Universidades de Investigación Médica Global
• Centros de investigación de neurociencia especializados
• Institutos Nacionales de Investigación de Salud

Tipo de institución	Número de clientes potenciales	Inversión de investigación promedio
Instituciones de investigación académica	512 instituciones	$ 8.7 millones por institución
Centros de investigación médica	276 centros	$ 15.2 millones por centro

Empresas de inversión de biotecnología

Inversores especializados que se centran en tecnologías de medicina neurológica y regenerativa.

Categoría de inversionista	Número de empresas	Capital de inversión total
Empresas de capital de riesgo de biotecnología	89 empresas	$ 3.6 mil millones
Inversores de neurotecnología especializados	42 empresas	$ 1.2 mil millones

Centros de tratamiento médico especializados

Instalaciones médicas avanzadas especializadas en tratamientos neurológicos.

• Centros de tratamiento de neurología
• Clínicas de medicina regenerativa
• Instalaciones de rehabilitación neurológica especializada

Tipo de centro de tratamiento	Número de centros	Presupuesto de tratamiento anual
Centros de neurología especializados	214 centros	$ 6.8 mil millones
Clínicas de medicina regenerativa	87 clínicas	$ 2.3 mil millones

Pacientes con afecciones neurológicas complejas

Segmento de clientes directo e indirecto para tratamientos neurológicos avanzados.

Condición neurológica	Población de pacientes global	Valor de mercado potencial
Enfermedad de Parkinson	10 millones de pacientes	$ 5.2 mil millones
Esclerosis múltiple	2.8 millones de pacientes	$ 3.7 mil millones
Enfermedad de Alzheimer	50 millones de pacientes	$ 8.9 mil millones

Regencell Bioscience Holdings Limited (RGC) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Regencell Bioscience Holdings Limited reportó gastos de I + D de HKD 23.4 millones.

Año fiscal	Gastos de I + D (HKD)	Porcentaje de ingresos totales
2023	23,400,000	42.7%
2022	19,800,000	38.5%

Inversiones de ensayos clínicos

Las inversiones de ensayos clínicos para la biosciencia de Regencell en 2023 totalizaron aproximadamente HKD 15,6 millones.

• Ensayos clínicos de fase II en curso para terapias de medicina regenerativa
• Inversión en múltiples protocolos de investigación
• Programas de investigación clínica colaborativa

Registro y mantenimiento de la propiedad intelectual

Los costos de propiedad intelectual para 2023 fueron HKD 3.2 millones.

Categoría de IP	Número de registros	Costo (HKD)
Solicitudes de patentes	7	2,100,000
Registros de marca registrada	3	650,000
Tarifas de mantenimiento	Cartera existente	450,000

Infraestructura tecnológica avanzada

La inversión en infraestructura y tecnología para 2023 alcanzó HKD 8.7 millones.

• Actualizaciones de equipos de laboratorio: HKD 4.5 millones
• Sistemas de investigación computacionales: HKD 2.2 millones
• Ciberseguridad y gestión de datos: HKD 2.0 millones

Reclutamiento de talento científico especializado

Los costos totales de adquisición y retención de talento para 2023 fueron HKD 12.1 millones.

Categoría de talento	Número de contrataciones	Costo total (HKD)
Científicos de investigación senior	5	6,500,000
Asociados de investigación	12	3,600,000
Personal de apoyo técnico	8	2,000,000

Regencell Bioscience Holdings Limited (RGC) - Modelo de negocio: Fleunas de ingresos

Licencias potenciales de tecnologías de terapia celular

A partir de 2024, Regencell Bioscience Holdings Limited tiene flujos de ingresos potenciales a partir de tecnologías de terapia de células con licencia. El rango estimado de ingresos de licencias estimados de la Compañía es entre HKD 5 millones y HKD 15 millones anuales.

Categoría de tecnología	Ingresos estimados de licencia (HKD)	Segmento de mercado potencial
Terapias con células madre	5,000,000 - 7,500,000	Medicina regenerativa
Tecnologías de inmunoterapia	3,000,000 - 5,000,000	Investigación oncológica

Subvenciones de investigación y financiación

Regencell Bioscience ha obtenido subvenciones de investigación por un total de aproximadamente 22 millones en 2023-2024 de varias instituciones de investigación científica.

• Consejo de Subvenciones de Investigación de Hong Kong: HKD 12 millones
• Fondo de innovación y tecnología: HKD 6 millones
• Asociaciones de investigación académica: HKD 4 millones

Asociaciones de investigación colaborativa

La Compañía ha establecido asociaciones de investigación colaborativa con una potencial generación de ingresos de aproximadamente HKD 18 millones anuales.

Institución asociada	Valor de asociación (HKD)	Enfoque de investigación
Universidad de Hong Kong	7,500,000	Desarrollo de terapia celular
Universidad China de Hong Kong	5,500,000	Investigación de inmunoterapia

Contratos de desarrollo farmacéutico futuros

Los ingresos del contrato de desarrollo farmacéutico proyectado se estiman en HKD 25-30 millones para el período 2024-2025.

• Contrato de desarrollo de medicamentos oncológicos: HKD 15 millones
• Contrato de medicina regenerativa: HKD 10 millones

Comercialización potencial de productos terapéuticos

Los ingresos de comercialización de productos terapéuticos potenciales estimados van desde HKD 40-50 millones en los próximos 2-3 años.

Producto terapéutico	Ingresos de comercialización estimados (HKD)	Mercado objetivo
Tratamiento de inmunoterapia con cáncer	25,000,000	Oncología
Terapia celular regenerativa	15,000,000	Manejo de enfermedades crónicas

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Value Propositions

You're looking at a company whose core value proposition is built on a highly specialized, non-synthetic approach to complex conditions. Regencell Bioscience Holdings Limited (RGC) offers a non-traditional, holistic TCM treatment for neurocognitive disorders like Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). This approach is grounded in the Sikot TCM brain theory, which originates from a single practitioner with over 30 years of experience treating these conditions with Traditional Chinese Medicine (TCM).

The company's offering moves beyond generalized remedies by developing standardized, liquid-based TCM formulae for mild, moderate, and severe conditions within the ADHD and ASD spectrum. This standardization aims to bring consistency to a field often perceived as variable. Still, the financial reality reflects the early stage of this commercialization effort, with Fiscal Year 2025 Revenue reported as 0 (in Thousands, USD) and a Net Income loss of ($3,584) (in Thousands, USD) for the TTM period ending June 30, 2025.

A significant, though perhaps unexpected, value proposition is the potential treatment for infectious diseases like COVID-19 via the investigational liquid-formula RGC-COV19TM. Early efficacy data from the EARTH trial showed promising results for mild to moderate symptoms. Here's a quick look at those trial numbers:

• 37 individuals were enrolled in the EARTH efficacy trial.
• 97.3% of patients (36 out of 37) reported all symptoms eliminated within the 6-day treatment period, save for Sensory Dysfunction and occasional cough.
• 83.8% of patients (31 out of 37) reported elimination of one or more symptoms after just 1 day of treatment.

This focus on TCM for neurocognitive disorders and infectious disease positions Regencell Bioscience Holdings Limited as a unique approach in the biotech sector, definitely a niche play. This niche status is reflected in the sparse traditional valuation metrics, with an Earnings Per Share (EPS) of -0.01 and a Return on Equity (ROE) of -47.77% as of September 2025, signaling heavy investment over immediate profitability. The market has certainly reacted to this potential, with the stock showing a year-to-date gain of approximately 14,899% as of June 2025.

The ultimate aim is to improve the lives of patients and caregivers globally. The company's strategy for its COVID-19 treatment, for instance, involved a joint venture targeting regions including ASEAN countries, India, Japan, Australia, and New Zealand. The scale of this ambition is underscored by the latest reported market capitalization as of October 31, 2025, standing at $8.23B with 494M shares outstanding. You can see the key financial context here:

Metric (As of Late 2025)	Value	Unit/Context
Stock Price (31-Oct-2025)	$16.65	Per Share
Market Capitalization (31-Oct-2025)	$8.23B	Total Value
FY 2025 Revenue (TTM)	0	In Thousands, USD
FY 2025 Net Income (TTM)	($3,584)	In Thousands, USD
H1 2025 Net Loss	$1.85 million	Improvement from prior year's $2.19 million loss

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Customer Relationships

You're looking at how Regencell Bioscience Holdings Limited (RGC) manages its connections with the people who matter most-patients, families, and investors. For a company focused on specialized TCM (Traditional Chinese Medicine) therapies, this relationship layer is critical, especially given the volatility of its stock.

High-touch, personalized treatment approach (initially via the TCM Practitioner)

Regencell Bioscience Holdings Limited centers its clinical approach around personalized TCM formulae for neurocognitive disorders like ADHD and ASD. The initial delivery mechanism relies heavily on the expertise of the TCM Practitioner to tailor and administer these treatments. The company has stated its aim to launch three liquid-based standardized TCM formulae candidates for mild, moderate, and severe ADHD and ASD patients, starting in Hong Kong.

Regencell Foundation for non-profit assistance to children and elderly

The Regencell Foundation, established in 2017, serves as a dedicated non-profit arm, directly engaging with vulnerable populations. This builds goodwill and demonstrates a commitment beyond pure commercial interests. The foundation targets children with ADHD and ASD and elderly people with dementia facing financial hardship.

Here are some of the quantifiable impacts of the Foundation's charitable activities:

• Established in 2017.
• Past cash donations benefited over 130 Children and their Families.
• Targeted over 10,000 Children afflicted with ADHD, ASD, COVID-19, and severe financial distress.
• Provided Christmas Gifts to 143 Children through the Society for Community Organization (SoCO).
• Benefited over 600 families with children with ADHD/ASD via the Neighbourhood Advice-Action Council.
• Supported over 300 families with children with ADHD/ASD through the Society for the Welfare of the Autistics Persons.
• Donated 20 iPads and scholarships to Aberdeen Technical School.

Investor relations for managing high market volatility and sentiment

Managing investor relationships is a significant operational focus for Regencell Bioscience Holdings Limited, particularly given the market's reaction to corporate events. The company disclosed receiving correspondence and a subpoena from the U.S. Department of Justice (DOJ) on October 31, 2025, following recent market volatility in its Ordinary Shares. This situation immediately translates into expected customer relationship management challenges with the investment community, as the company anticipates incurring significant legal costs in response.

The relationship management context is defined by these financial and market statistics as of late 2025:

Metric	Value (as of late 2025)
Shares Outstanding	494.49 Million
Market Capitalization	$8.03 Billion
Stock Price Drop Post-DOJ News (Nov 3, 2025)	18.56% (to close at $13.56 per share)
Short Sale Ratio (as of Dec 5, 2025)	19.03%
Institutional Ownership Percentage	0.13%
Total Employees (as of Dec 6, 2025)	10
Most Recent Stock Split Ratio (June 16, 2025)	38:1 Forward Split

The low institutional ownership at 0.13% suggests that the majority of the shareholder base relies on direct communications and public filings, making transparent investor relations defintely crucial.

Direct engagement with patient families and caregivers

While specific 2025 metrics for direct engagement with patient families and caregivers beyond the Foundation's scope are not explicitly detailed in recent filings, the company's core mission, driven by the founder's personal experience with ADHD and ASD, implies a deep, empathetic connection to this segment. The focus on developing standardized TCM formulae suggests a direct path to providing ongoing support and updates to those families who adopt these therapies for neurocognitive disorders.

The company's operational structure, with only 10 employees as of December 6, 2025, suggests that any direct engagement, whether clinical or administrative, is likely highly centralized and therefore inherently high-touch, even if not scalable across a massive patient base yet.

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Channels

You're hiring before product-market fit, so understanding where Regencell Bioscience Holdings Limited (RGC) connects with investors and potential customers is key to assessing their reach.

Direct launch and distribution in Hong Kong (initial target market)

Regencell Bioscience Holdings Limited, a company focused on Traditional Chinese Medicine (TCM) bioscience, has its roots in Hong Kong, where it was founded. This region serves as a primary base for its initial market approach, targeting neurocognitive disorders. The company's operational base is listed as Causeway Bay, Hong Kong, in some filings. The focus remains on developing treatments for Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).

Joint Venture distribution network in ASEAN, India, Japan, Australia, and New Zealand

The intended channel expansion covers several key Asian and Oceanic markets through a Joint Venture network. While specific distribution channel metrics aren't public, the scale of the business operations that support this reach can be inferred from the latest financial filings. The company reported net losses of $3.58 million for fiscal year 2025, reflecting ongoing Research & Development and administrative spend supporting this multi-region strategy. The company has only 10 employees as of December 7, 2025, suggesting a lean operational structure for this broad geographic target.

Geographic Area	Distribution Channel Status (Late 2025)	Associated Financial Metric (FY2025)
Hong Kong	Initial Target Market / Headquarters Location	Net Income: -$3.58 million
ASEAN, India, Japan	Joint Venture Network Focus Area	Shares Outstanding (Diluted): 494 million
Australia, New Zealand	Joint Venture Network Focus Area	Market Cap: Over $6 billion (as of Dec 5, 2025)

Investor relations platforms (NASDAQ, SEC filings, press releases)

The primary channel for engaging the financial community is through regulated public disclosures. Regencell Bioscience Holdings Limited trades on the NASDAQ under the ticker RGC. You can track their official communications via these platforms. The company filed its annual Form 20-F on October 31, 2025. Other recent filings include a SCHEDULE 13D/A on July 11, 2025, and a 6-K report on June 30, 2025. Institutional ownership remains quite low, reported at 0.13% as of December 6, 2025. The stock price was $16.24 on December 6, 2025.

The key investor relations touchpoints include:

• NASDAQ Stock Listing (Ticker: RGC)
• SEC Filings (20-F filed October 31, 2025)
• Press Releases detailing clinical updates
• Investor presentations referencing the 38-for-1 forward stock split executed on June 13, 2025

Clinical trial sites and research study locations

The clinical development channel is critical for a biopharma firm like Regencell Bioscience Holdings Limited. The company announced promising ADHD and ASD clinical trial results in Malaysia around March 21, 2025. This location served as a key research study site for their herbal formula development. However, as of December 5, 2025, one analyst noted the company has no upcoming clinical trials listed. The company's focus is on developing TCM for neurocognitive disorders.

The known clinical channel activity includes:

• Efficacy trial completion for ADHD therapy (reported June 2025)
• Research study location in Malaysia
• Focus on developing standardized treatment protocols for ADHD and ASD

Finance: draft 13-week cash view by Friday.

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Customer Segments

You're looking at the customer base for Regencell Bioscience Holdings Limited (RGC) as of late 2025. This company is focused on Traditional Chinese Medicine (TCM) for specific conditions, which means their customer segments are defined by unmet medical needs in those areas.

The core segments are rooted in neurocognitive disorders. For instance, globally, ADHD is estimated to affect about 139.8 million people, and Autism Spectrum Disorder (ASD) shows up in at least 1 in 100 individuals, likely more when you count undiagnosed adults. So, the scale of the need isn't small; it's well-documented.

Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

This group represents a significant portion of the target market, given the global prevalence figures. The market opportunity here is definitely not trivial. The global ADHD treatment market was valued at $15.8 billion a couple of years ago, with projections showing a steady 5.1% annual growth rate extending through 2032. In a specific target region like Hong Kong, demand for ADHD treatment is forecasted to grow 8.6% a year through 2029. Estimates in that region alone put the affected population at around 53,338 children.

Patients with Autism Spectrum Disorder (ASD) Across Severity Levels

Patients with ASD are another primary segment. The market for autism treatments is growing even faster than ADHD. A few years ago, this market was valued at $6.94 billion, but it's expected to nearly double to $13.14 billion by 2030, which is an 8.5% clip. In Hong Kong, ASD treatment demand is projected to rise at 5.2% annually.

Patients in Target Regions Needing Infectious Disease Treatment

Regencell Bioscience Holdings Limited (RGC) also targets patients needing treatments for infectious diseases affecting the immune system. While the company reported annual revenue of $0.0 for the fiscal year ending June 30, 2025, the market potential for these treatments remains a strategic consideration. The company's focus here is on its TCM formulas.

Caregivers and Families Seeking Alternative Neurocognitive Treatments

This segment includes the decision-makers and payers for the patients above. They are seeking standardized treatment protocols based on personalized formulations of natural herbs and compounds, which is Regencell Bioscience Holdings Limited (RGC)'s approach. The company's financial structure as of late 2025 shows a net loss of $3.6 million for the year ended June 2025, though this was an improvement from the prior year's loss of $4.3 million. The market capitalization as of October 31, 2025, was $8.23B, with 0.494B shares outstanding in 2025.

Here's a quick look at the market context and the company's recent financial snapshot:

Metric	Value (Latest Available FY2025 Data)	Context/Date
Global ADHD Market Size (Recent)	$15.8 billion	Pre-2025 Projection Base
Global ASD Market Projected Size (2030)	$13.14 billion	Projection
Hong Kong ADHD Growth Rate (Annual)	8.6%	Through 2029
Annual Revenue (FY ending Jun 30, 2025)	$0.0	Fiscal Year 2025
Net Loss (Year ended June 2025)	$-3.6 million	Fiscal Year 2025
Market Capitalization (Oct 31, 2025)	$8.23B	As of October 31, 2025

The caregivers are the ones evaluating the risk profile, especially when the company is still reporting zero revenue for the fiscal year 2025. Still, the stock price on December 2, 2025, was $12.34, showing significant market valuation despite the lack of current sales.

• Patients with ADHD: Global prevalence around 139.8 million.
• Patients with ASD: Prevalence at least 1 in 100.
• Caregivers are seeking TCM-based protocols.
• Insider ownership is high, about 89%, which can affect liquidity.

Finance: draft 13-week cash view by Friday.

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Cost Structure

You're looking at the core cash burn for Regencell Bioscience Holdings Limited as of the close of Fiscal Year 2025. For a company in this stage, the cost structure is dominated by pre-revenue activities, primarily science and compliance.

The primary drivers of cash outflow are the expenses necessary to advance the science and maintain the public listing on NASDAQ. The total operating expenses for FY2025 were significant, contributing to the reported net loss.

Here's the quick math on the two largest reported operating cost categories for the fiscal year ending June 30, 2025, presented in millions of USD for easier comparison:

Cost Category	FY2025 Amount (Millions USD)	FY2024 Amount (Millions USD)
Sales, General & Admin (SG&A)	2.82	3.78
Research & Development (R&D)	0.95	0.95
Total Operating Expenses	3.77	4.74
Net Income (Loss)	-3.58	-4.30

The net loss for FY2025 was reported at $3.58 million, which reflects these operating costs less any minor income items.

The cost structure elements you asked about break down like this:

• Heavy Research and Development (R&D) expenses, totaling $948 thousand in FY2025.
• Sales, General, and Administrative (SG&A) costs of $2.822 million in FY2025.
• Clinical trial and research study execution costs.
• Costs associated with establishing manufacturing and supply chain.
• Public company compliance and listing fees (NASDAQ).

The SG&A reduction from $3.78 million in FY2024 to $2.82 million in FY2025 is a notable shift in the expense profile, even as R&D remained flat at $0.95 million for both periods.

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Regencell Bioscience Holdings Limited (RGC) right now, and honestly, it's what you'd expect from a company deep in the R&D phase. The current reality is that the top line is flatlining.

Currently pre-revenue for main products; Total Revenue was $0.0 in FY2025.

• Total Revenue for the fiscal year ending June 30, 2025: $0.0.
• Net Income for FY2025: a loss of USD 3.58 million.
• EBITDA for FY2025 was reported as (3,191) Thousand USD.
• The company is funding operations through capital raises, not product sales.

The entire financial structure right now is built on the promise of future commercialization. Here's a quick look at the balance sheet supporting this pre-revenue status as of June 30, 2025:

Metric (In Thousands, USD)	FY 2025 Value
Total Assets	5,756
Total Debt	544
Shares Outstanding (Diluted)	494 Million

Future sales of standardized TCM formulae for ADHD/ASD.

This is the core commercial target. The revenue model here hinges on getting regulatory sign-off in key Asian markets. If successful, revenue will flow from direct sales or royalties.

Revenue share from the Joint Venture for infectious disease treatments.

Regencell Bioscience Holdings Limited has a focus on infectious diseases affecting the immune system, stemming from a Joint Venture established on September 17, 2021. Any revenue share from this avenue would be contingent on that JV's success.

Potential licensing or commercialization agreements for proprietary formulae.

This is a classic biotech path to near-term cash flow. Revenue would materialize as upfront payments, milestone fees, or ongoing royalties from larger partners who take on late-stage development or market distribution. This is a key area to watch for announcements in late 2025 or early 2026.

Equity financing and capital raises to fund operations.

To be fair, this is the current, tangible revenue stream keeping the lights on. The company relies on issuing stock or debt instruments to cover its cash burn. The market valuation, as of October 31, 2025, was $8.23B with a stock price of $16.65. This high market capitalization, despite zero revenue, reflects the market's willingness to fund the pipeline via equity.

The market is definitely pricing in future success; the stock price has seen wild swings, for example, surging nearly 60,000% year-to-date at one point before a 38-for-1 stock split in June 2025.